Beckman Coulter introduces the Microfuge 16 benchtop centrifuge that spins at 16,163 x g (14,800 RPM) for fast pelleting or isolation of DNA, RNA, proteins, and viruses.
Sigma-Aldrich’s ProteoPrep 20 LC Column removes more biological noise, allowing proteomic researchers to delve deeper into the plasma proteome with less fractions to assess in the analysis phase.
Gatan Inc. launched th XuM for its range of imaging products for the scanning electron microscope. The XuM utilizes a SEM as a host instrument to enable x-ray imaging of the internal structure of objects with resolutions down to less than 100nm.
Nikon Instruments’ BioStation CT is a self-contained cell culture observation device and monitoring system to conduct live cell imaging locally or by remote operation over a network.
JEOL’s JSM-7001F features a lens field emission gun that delivers more than 200 nA of beam current to the sample.
Leica’s SD6000 Spinning Disk Confocal module is designed for observing differentiation processes, intracellular transport, cell division, and dynamics of the cytoskeleton over long periods of time.
The Nova NanoSEM 30 series from FEI is a field emission SEM series that features new low kV performance, high current, and high-resolution operation in low vacuum.
Carl Zeiss SMT presents the newly designed EVO LS microscope series scanning electron microscope (SEM) built on the foundations laid by the EVO series.
The FDA and the Department of Defense (DoD) announced plans to share data and expertise related to the review and use of FDA-regulated drugs, biologics, and medical devices.
Targacept announced that its strategic collaborator AstraZeneca has initiated a Phase IIb clinical trial of AZD3480 (TC-1734) in cognitive deficits in schizophrenia.
Gene Logic entered into a drug repositioning and development agreement with Merck Serono, a division of Merck KGaA of Germany, to seek alternative development paths for several Merck Serono drug candidates.
Bristol-Myers Squibb and Pfizer finalized an agreement for the worldwide collaboration to research, develop, and commercialize DGAT-1 inhibitors.Pfizer will be responsible for all research and early-stage development activities for the metabolic disorders program, and the companies will jointly conduct Phase 3 development and commercialization activities.
Investigators at Washington University School of Medicine, St. Louis, Mo., succeeded in separating the good effects of opiate drugs from the unwanted side effects of those drugs.
Researchers have shown functional nerve cells can be generated from astroglia, a type of supportive cells in the brain by means of special regulator proteins.